Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
For some, pharmacogenomic tools can add context
Fatty liver disease In 2025, Wegovy received an additional FDA approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) a serious form of fatty liver disease driven by insulin resistance
"It makes sense that we need to treat these people if they want that treatment." Currently, Ozempic is only available on the PBS for patients with type 2 diabetes, which is what GLP-1 medications were originally developed to treat
Zepbound remains a once-weekly tirzepatide injection
This landmark study demonstrated semaglutides effectiveness for weight loss while highlighting the importance of structured nutrition support for optimal body composition outcomes
